STOCK TITAN

Vir Biotechnology, Inc. - VIR STOCK NEWS

Welcome to our dedicated page for Vir Biotechnology news (Ticker: VIR), a resource for investors and traders seeking the latest updates and insights on Vir Biotechnology stock.

Vir Biotechnology, Inc. (VIR) pioneers immunology solutions targeting complex infectious diseases through innovative platforms including antibody therapies, T cell engineering, and siRNA technology. This dedicated news hub provides investors and industry stakeholders with timely updates on clinical developments, strategic partnerships, and regulatory milestones.

Access authoritative updates on VIR's research pipeline, financial performance announcements, and scientific breakthroughs in infectious disease management. Our curated collection ensures transparent access to press releases spanning clinical trial progress, collaborative initiatives, and patent filings.

Key updates include advancements in hepatitis B/HIV therapies, influenza A research, and platform technology licensing agreements. Bookmark this page to efficiently monitor VIR's contributions to biotechnology and its evolving position in global health innovation.

Rhea-AI Summary

Vir Biotechnology has published new research identifying the N-terminal domain (NTD) of the SARS-CoV-2 spike protein as a target for neutralizing antibodies, with varying efficacy across emerging variants. The findings highlight the NTD's potential role in immune evasion and suggest the need for therapies with high resistance barriers. The investigational antibody VIR-7831, currently in Phase 3 trials, targets a conserved area of the receptor binding domain (RBD) and is designed for effectiveness against SARS-CoV-2 and its variants. Recent studies emphasize the importance of broadening targets to enhance vaccine and therapeutic strategies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.96%
Tags
none
-
Rhea-AI Summary

Eli Lilly, Vir Biotechnology, and GlaxoSmithKline have announced a collaboration to study two COVID-19 therapies in low-risk patients. The expanded BLAZE-4 trial will investigate the efficacy of bamlanivimab (700mg) with VIR-7831 (500mg), marking the first time monoclonal antibodies from different companies will be combined. Bamlanivimab is authorized for emergency use against COVID-19, while VIR-7831 is still investigational. The collaboration aims to provide insights into the potential benefits of this combination therapy amidst ongoing COVID-19 challenges.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.35%
Tags
covid-19
-
Rhea-AI Summary

Eli Lilly (LLY), Vir Biotechnology (VIR), and GlaxoSmithKline (GSK) announced a collaboration to evaluate the combination of their COVID-19 therapies in low-risk patients with mild to moderate COVID-19. The expanded BLAZE-4 trial will assess bamlanivimab (700mg) with VIR-7831 (500mg), both neutralizing antibodies targeting SARS-CoV-2. This marks the first cross-company monoclonal antibody collaboration. Bamlanivimab is authorized for emergency use, while VIR-7831 is investigational. The trial aims to determine if this combination therapy can improve treatment outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.35%
Tags
covid-19
Rhea-AI Summary

Vir Biotechnology announced promising initial data from its ongoing trial of VIR-3434 for chronic HBV infection. In a blinded cohort of eight patients, six achieved a significant mean reduction of 1.3 log10 IU/mL in HBsAg by day eight after a single 6 mg dose. This unexpected efficacy at low dosage demonstrates VIR-3434's potential as both a neutralizing antibody and a therapeutic vaccine. The trial is designed to evaluate safety and efficacy in chronic HBV patients and will progress with additional studies, including a Phase 2 trial combining VIR-3434 with VIR-2218.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
74.32%
Tags
-
Rhea-AI Summary

Vir Biotechnology and Gilead Sciences have initiated a Phase 2 clinical trial to explore combination therapies for chronic hepatitis B virus (HBV). The trial will evaluate various combinations, including Gilead’s selgantolimod and Vir’s VIR-2218. This collaboration aims to develop a functional cure for HBV, which affects over 290 million people globally. The primary goal is to achieve a functional cure, defined by the loss of hepatitis B surface antigen from the serum. Both companies retain rights to their respective candidates. Safety and efficacy of these investigational drugs have yet to be established.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.41%
Tags
none
-
Rhea-AI Summary

Gilead Sciences (NASDAQ: GILD) and Vir Biotechnology (NASDAQ: VIR) announced a clinical collaboration to explore new therapeutic combinations for chronic hepatitis B virus (HBV). A Phase 2 trial will evaluate therapies involving Gilead's selgantolimod, VIR's VIR-2218, and a PD-1 antagonist. The study aims to achieve a functional cure, defined by the loss of hepatitis B surface antigen (HBsAg) and HBV DNA. Both firms retain rights to their products and will consider future studies based on Phase 2 results. Current therapies require lifelong treatment for over 290 million HBV patients globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.41%
Tags
none
Rhea-AI Summary

Vir Biotechnology is advancing its collaboration with GlaxoSmithKline to evaluate VIR-7832, a monoclonal antibody aimed at treating COVID-19. The Phase 1b/2a clinical trial, which starts in Q1 2021, will assess VIR-7832's ability to clear infected cells and enhance T cell function. This trial will be conducted through the AGILE initiative across multiple UK sites. This study builds on the first antibody, VIR-7831, which is already in Phase 3 trials, highlighting a robust pipeline focused on addressing the pandemic.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.41%
Tags
covid-19
-
Rhea-AI Summary

Vir Biotechnology announced the initiation of a Phase 1 clinical trial for VIR-1111, an investigational HIV T cell vaccine, in late December 2020. This trial is a result of a decade-long collaboration with Oregon Health & Science University and the Bill & Melinda Gates Foundation. The trial aims to assess the safety and immunogenicity of VIR-1111, which is designed to elicit a strong immune response by generating CD4 and CD8 T cells to attack HIV-infected cells. The study involves healthy adults previously infected with human cytomegalovirus.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.68%
Tags
-
Rhea-AI Summary

Vir Biotechnology, a clinical-stage immunology company, announced that CEO George Scangos, Ph.D., will present virtually at the 39th Annual J.P. Morgan Healthcare Conference on January 12th at 11:00 am PT/2:00 pm ET. The presentation will be accessible through a live webcast on the Vir website and will be archived for 30 days. Vir focuses on treating and preventing infectious diseases through innovative immunology technologies, with a pipeline targeting SARS-CoV-2, hepatitis B, influenza A, HIV, and tuberculosis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.53%
Tags
conferences
Rhea-AI Summary

Vir Biotechnology and GlaxoSmithKline announced the initiation of a Phase 3 clinical trial for VIR-7831, an investigational monoclonal antibody aimed at treating hospitalized adults with COVID-19. The trial, part of the NIH’s ACTIV program, will assess safety and efficacy against standard care. A total of 300 participants will receive either VIR-7831 or a placebo, with follow-ups for clinical status. This therapy has shown potential in neutralizing SARS-CoV-2, which could contribute significantly to treatment options as cases surge globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.68%
Tags
covid-19
Vir Biotechnology, Inc.

Nasdaq:VIR

VIR Rankings

VIR Stock Data

759.35M
101.72M
12.01%
76.71%
5.66%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SAN FRANCISCO